Conclusion
In these cases, we would like to emphasize that the combination of lamotrigine and valproic acid to control seizures can cause life-threatening skin reactions such as SJS/TEN and DRESS syndrome. the physicians should be alert and have to be aware of that when prescribing antiepileptic drugs.
References
  1. A.WArshavsky, A.Eilam, and R.Gilad. Lamotrigene as a monotherapy in clinical practice: efficacy of various dosages in epilepsy. Brain and Behaviour. Vol6. N°3. Article e00419.
  2. J. R. Calabrese, J. R. Sullivan, C. L. Bowden et al., “Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management,” Journal of Clinical Psychiatry, vol. 63, no. 11, pp. 1012–1019, 2002.
  3. O. Egunsola, I. Choonara, and H. M. Sammons, “Safety of lamotrigine in paediatrics: a systematic review,” BMJ Open, vol. 5, no. 6, article e007711, 2015.
  4. Noguera-Morel L, Hernandez-Martin A, Torrelo A. Cutaneous drug reactions in the pediatric population. Pediatr Clin North Am 2014; 61: 403-26.
  5. Gomes E, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, et al. Drug hypersentivity in children : report from the pediatric Task Force of the EAACI Drug Allergy Interest Group. Allergy 2016; 71: 149-61.
  6. Teo YX, Walsh SA. Severe drug reactions. Clin Med 2016; 16: 79-83.
  7. Hoetzenecker. W, Nägeli MM, Mehra ET, Jensen AN, Saulite I, Schimid-Grendelmeier P, et al. Adverse cutaneous drug eruptions : current understanding. Semin Immunopathol 2016 ; 38 : 75-86.
  8. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol 2013;68:693.e1-693.e14. quiz 706-708.
  9. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature review. Am J Med 2011;124:588-97.
  10. Marcus N, Smuel K, Almog M, Prais D, Straussberg R, Landau D, et al. Successful Intravenous Immunoglobulin Treatment in Pediatric Severe DRESS Syndrome. J Allergy Clin Immunol Pract. août 2018;6(4):1238‑42.
  11. Yapici AK, Fidanci MK, Kilic S, Balamtekin N, Mutluay Arslan M, Yavuz ST, et al. Stevens-Johnson Syndrome triggered by a combination of clobazam, lamotrigine and valproic acid in a 7-year-old child. Ann Burns Fire Disasters. 30 sept 2014;27(3):121‑5.
  12. Mockenhaupt M, Viboud C, Dunant A et al.: Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCARstudy. J Invest Dermatol, 128: 35-44, 2008.
  13. French LE: Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int, 55: 9-16, 2006.
  14. Lamotrigine-Valproic Acid Interaction Leading to Stevens-Johnson Syndrome - PubMed [Internet]. [cité 25 févr 2021]. Disponible sur:https://pubmed.ncbi.nlm.nih.gov/30228819/
  15. W. Lu and J. P. Uetrecht, “Possible bioactivation pathways of lamotrigine,” Drug Metabolism and Disposition, vol. 35, no. 7, pp. 1050–1056, 2007.
  16. M. Lalic, J. Cvejic, J. Popovic et al., “Lamotrigine and valproate pharmacokinetics interactions in epileptic patients,”European Journal of Drug Metabolism and Pharmacokinetics, vol. 34, no. 2, pp. 93–99, 2009
  17. A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G. Dickinson, and J. O. Miners, “In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction,” Drug Metabolism and Disposition, vol. 34, no. 6, pp. 1055–1062, 2006.
  18. L. W. Wormhoudt, J. N. Commandeur, and N. P. Vermeulen, “Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity,” Critical Reviews in Toxicology, vol. 29, no. 1, pp. 59–124, 1999.
  19. O. Spiegelstein, D. L. Kroetz, R. H. Levy et al., “Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid,” Pharmaceutical Research, vol. 17, no. 2, pp. 216–221, 2000.
  20. M. Rosa, P. Bonnaillie, and H. Chanteux, “Prediction of drug–drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition,” Xenobiotica, vol. 46, no. 12, pp. 1076–1084, 2016.
  21. D. Diki´c, D. Jutri´c, and K. Dominko, “)e dual nature of the antiepileptic drug valproic acid, with possible beneficial effects in Alzheimer’s disease,” SEEMEDJ, vol. 1, no. 1, pp. 74–89, 2017.
  22. X. Wang, B. Iv, H. Wang et al., “Lamotrigine-induced severe cutaneous adverse reaction: update data from 1999–2014,” Journal of Clinical Neuroscience, vol. 22, no. 6, pp. 1005–1011, 2015.
  23. K. Maduemem, A. Vatca, T. O’Neill, and D. Buckley, “Stevens– Johnson syndrome induced by combination of lamotrigine and valproic acid in a 9-year-old boy,” Irish Medical Journal, vol. 110, no. 6, p. 586, 2017.
  24. Dibek Misirlioglu E, Guvenir H, Bahceci S, Haktanir Abul M, Can D, Usta Guc BE, et al. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study. J Allergy Clin Immunol Pract. juin 2017;5(3):757‑63.